Cargando…
Outcome measures and treatment effectiveness in late onset myasthenia gravis
BACKGROUND: Recently different subtypes of myasthenia gravis (MG) have been described. They differ for clinical features and pathogenesis but the prognosis and response to treatment is less clear. The aim of the study was to evaluate outcome and treatment effectiveness including side effects in late...
Autores principales: | Pasqualin, Francesca, Guidoni, Silvia V., Ermani, Mario, Pegoraro, Elena, Bonifati, Domenico M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650071/ https://www.ncbi.nlm.nih.gov/pubmed/33324944 http://dx.doi.org/10.1186/s42466-020-00091-z |
Ejemplares similares
-
Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII)
por: Pasqualin, Francesca, et al.
Publicado: (2021) -
Development and validation of the Myasthenia Gravis TeleScore (MGTS)
por: Pasqualin, F., et al.
Publicado: (2022) -
Impact of COVID-19 on a group of patients with myasthenia gravis
por: Sansone, Giulio, et al.
Publicado: (2021) -
P-1
Prognostic factors and course of myasthenia
gravis
por: Albertini, E., et al.
Publicado: (2011) -
Late-onset myasthenia gravis is predisposed to become generalized in the elderly
por: Sakai, Waka, et al.
Publicado: (2016)